痴呆症:从ICD-10到ICD-11的变化
Frank Jessen1,2, Karl Broich3
1Department of Psychiatry, Faculty of Medicine, University Hospital Cologne, Kerpener Straße 62, 50937, Cologne, Germany. frank.jessen@uk-koeln.de.
Der Nervenarzt
|October 14, 2025
概括
疾病和相关健康问题的国际统计分类第11版 (ICD-11) 提供了改进的痴呆症分类,包括严重程度和症状重点. 然而,它缺乏专家临床标准和神经退行性疾病的生物标志物集成.
科学领域:
- 神经学 神经学
- 医学分类系统 医学分类系统
背景情况:
- 疾病与相关健康问题的国际统计分类第10版 (ICD-10) 在分类痴呆症方面存在局限性.
- 了解神经退行性疾病的进步需要更新的分类系统.
研究的目的:
- 与ICD-10相比,评估国际疾病和相关健康问题统计分类版本11 (ICD-11) 在痴呆症分类中的概念进步.
- 确定ICD-11中需要改进的领域,包括痴呆症的临床标准和生物标志物.
主要方法:
- 对神经认知障碍的ICD-11和ICD-10分类结构进行比较分析.
- 审查ICD-11关于"神经认知障碍"的章节,以准确编码和纳入诊断特征.
- 评估将专家开发的临床标准和生物标志物信息纳入ICD-11中的情况.
主要成果:
- ICD-11引入了严重程度等级,并强调精神/行为症状,以便更精确地编码痴呆症.
- 在ICD-11中,轻度神经认知障碍作为前发性痴呆状态的新类别被列入ICD-11.
- 在ICD-11中,对于特定的痴呆症 (例如,前性痴呆症,勒维体病) 没有充分纳入专家临床标准,也没有提到用于病因诊断的生物标志物.
结论:
- 在痴呆症分类方面,ICD-11代表了与ICD-10相比显著的概念改进.
- 需要对ICD-11进行进一步的更新,以整合已建立的临床标准和在痴呆症诊断中生物标志物的作用.
- 鉴于神经退行性疾病研究的快速进展,定期修订ICD-11至关重要.
相关概念视频
Diagnostic and Statistical Manual of Mental Disorders (DSM)
844
The Diagnostic and Statistical Manual of Mental Disorders (DSM) serves as the primary classification system for mental health disorders, providing standardized diagnostic criteria for clinicians and researchers. First published by the American Psychiatric Association (APA) in 1952, the DSM has undergone several revisions to reflect evolving psychiatric understanding. The fifth edition, DSM-5, released in 2013, introduced key updates that expanded diagnostic categories and modified diagnostic...
844
Dementia
480
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
480
Intellectual Disability
580
Intellectual disability (ID) is a neurodevelopmental condition characterized by deficits in intellectual and adaptive functioning that manifest during the developmental period. This condition encompasses challenges in reasoning, memory, problem-solving, and learning, accompanied by impairments in everyday life skills, such as communication, self-care, and social interactions. Intellectual disability affects approximately 1% of the population in the United States, impacting an estimated 5...
580
Alzheimer's Disease: Overview
1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Heart Failure IV: Classification and Diagnostic Evaluation
281
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
281
Alzheimer's Disease: Treatment
736
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
736


